HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Abortion Pills Offered Nonprescription By E-Commerce Firms FDA Warned

Executive Summary

One active ingredient in unapproved drugs sold by two e-commerce operations, identified by FDA as Rabold and AidAccess.org, is mifepristone, also known as RU-486 in the only drug with the ingredient approved for an indication of medical termination of early pregnancy, Danco Laboratories' Mifeprex. Firms' websites offer sales of products without requiring customers to submit prescriptions.

You may also be interested in...

Crackdown On Illegal Online Pharmacies Like Playing Internet 'Whack-A-Mole'

US FDA sends warning letters to online businesses operating a total of 465 websites selling unapproved Rx drugs for indications including breast cancer, chicken pox and pain relief. Warning letters were part of Interpol's annual Operation Pangea against online sales of illegal medical products; this year, US and 115 other countries made 859 arrests worldwide and seized $14m in potentially dangerous pharmaceuticals.

Oral Contraceptive OTC Proposal Moves Closer With Start Of Actual Use Study

HRA Pharma started recruiting in April for an actual use trial, using oral contraceptives with norgestrel 0.075 mg, and expects to complete its study in April 2019, according to clinicaltrials.gov's database. Advocacy group Ibis Reproductive Health, which is working with HRA on an NDA for an OTC oral contraceptive, called the start of the study a "pivotal moment" in moving birth control drugs out of Rx-only.

Off-Label Is Off The Docket: Supreme Court Leaves RU-486 Flexibility Intact

High court declines to intervene in dispute over Arizona law that would restrict use of abortion drug; court also denies Roche petition for review of Boniva patent ruling.

Related Content


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts